Clinical research of EGFR inhibitors and related dermatologic toxicities.

摘要: An acneiform-like skin toxicity is commonly observed in patients with solid tumors treated epidermal growth factor receptor inhibitors (EGFRIs). This symptomatic rash related to (EGFR) inhibition the skin. A positive relation between presence and severity of treatment-related survival has been consistently all EGFRIs approved for clinical use. These findings suggest that may be a useful surrogate marker successful EGFR benefit therefore possible use identifying most likely from therapy, as well guide dose adjustments. Increasing drug until appears being studied. Further studies are needed thoroughly evaluate value benefit. Current treatments empirical oriented toward mitigating symptoms not validated by well-controlled trials. Rational based on biological mechanisms must developed tested